Sage Journals: Discover world-class research

Abstract

In the past 10 years, mortality from acute myocardial infarction has not decreased despite the widespread introduction of percutaneous coronary intervention. The reason for this situation is the absence in clinical practice of drugs capable of preventing reperfusion injury of the heart with high efficiency. In this regard, noteworthy natriuretic peptides (NPs) which have the infarct-limiting effect, prevent reperfusion cardiac injury, prevent adverse post-infarction remodeling of the heart. Atrial natriuretic peptide does not have the infarct-reducing effect in rats with alloxan-induced diabetes mellitus. NPs have the anti-apoptotic and anti-inflammatory effects. There is indirect evidence that NPs inhibit pyroptosis and autophagy. Published data indicate that NPs inhibit reactive oxygen species production in cardiomyocytes, aorta, heart, kidney and the endothelial cells. NPs can suppress aldosterone, angiotensin II, endothelin-1 synthesize and secretion. NPs inhibit the effects aldosterone, angiotensin II on the post-receptor level through intracellular signaling events. NPs activate guanylyl cyclase, protein kinase G and protein kinase A, and reduce phosphodiesterase 3 activity. NO-synthase and soluble guanylyl cyclase are involved in the cardioprotective effect of NPs. The cardioprotective effect of natriuretic peptides is mediated via activation of kinases (AMPK, PKC, PI3 K, ERK1/2, p70s6 k, Akt) and inhibition of glycogen synthase kinase 3β. The cardioprotective effect of NPs is mediated via sarcolemmal K_ATP channel and mitochondrial K_ATP channel opening. The cardioprotective effect of brain natriuretic peptide is mediated via MPT pore closing. The anti-fibrotic effect of NPs may be mediated through inhibition TGF-β1 expression. Natriuretic peptides can inhibit NF-κB activity and activate GATA. Hemeoxygenase-1 and peroxisome proliferator-activated receptor γ may be involved in the infarct-reducing effect of NPs. NPs exhibit the infarct-limiting effect in patients with acute myocardial infarction. NPs prevent post-infarction remodeling of the heart. To finally resolve the question of the feasibility of using NPs in AMI, a multicenter, randomized, blind, placebo-controlled study is needed to assess the effect of NPs on the mortality of patients after AMI.

Keywords

heart ischemia reperfusion natriuretic peptides

Introduction

Despite the widespread use of coronary artery stenting in clinical practice, mortality from acute myocardial infarction is about 5% and has not decreased in recent years.^1
-3 The widely used percutaneous coronary intervention (PCI) allows for recanalization of the infarct-related coronary artery in 95% of cases.⁴ With the use of PCI in clinical practice, reperfusion injuries of the heart play an increasing role, accounting for up to 50% of infarct size.⁵ Hence, a search is underway for new pharmacological approaches to protect the heart from ischemia-reperfusion injuries: some of these approaches are based on the use of endogenous mechanisms to increase heart’s tolerance to ischemia and reperfusion.^6,7 Of particular interest in this regard are natriuretic peptides (NPs). The objective of this review is to summarize published data on the mechanisms of the cardioprotective effect of NPs, and to assess perspectives for the clinical use of NPs.

In 1981, the de Bold’s group found that rat atrial extracts had a diuretic effect and enhanced urinary sodium excretion.⁸ Two years later they found that a 28-amino acid peptide had a natriuretic effect.⁹ According to more recent data, it is composed of 29 amino acids.¹⁰ In 1984, another group of researchers discovered that there are 2 atrial natriuretic peptides (ANPs): α-ANP and β-ANP.^11,12 In 1988, brain natriuretic peptide (BNP) was isolated from pig brain tissue and it was found that this molecule consists of 32 amino acids.^10,13 In 1990, a third type of natriuretic peptide: C-type natriuretic peptide (CNP), consisting of 22 amino acids, was isolated from pig’s brain (Figure 1).¹⁴ It was later shown that ANP and BNP are synthesized in large quantities in myocardial tissue: ANP in the atrium and BNP in the ventricle and in the atrium.^15,16 Although ANP was found in both atrial and ventricular tissues, the ANP levels in the atria are 250–1,000 times higher than those in the ventricles.¹⁶ The BNP level is higher in the atria, but since the weight of the atria is much less than the ventricles, the ventricular content of BNP is 30% higher than in the whole heart.¹⁶ It has been demonstrated that human cardiac fibroblasts also express BNP.¹⁷ It was found that CNP is synthesized not only in the brain, but also in peripheral organs and tissues.^15,16 ANP and BNP are mainly synthesized by atrial and ventricular cells, and enter the blood stream from there.¹⁰ CNP is synthesized by endothelial cells, including endothelial cells of the coronary arteries,¹⁸ and it is believed that the endothelium is the main source of circulating CNP.^19,20 NPs are sensitive to enzymatic hydrolysis. Hence, their half-lifes in plasma are short, for CNP 2.6 min,²¹ for BNP 20 min,²² and for ANP 2.4 ± 0.7 min.²³

Figure 1.

Types of natriuretic peptides (NPs), receptors (NPRs) and their regulatory functions (Reg).

It is well known that NPs regulate renal function, affect nervous and endocrine signaling, energy metabolism, and the cardiovascular system, and play an important role in the regulation of blood pressure (BP) (Figure 1).^16,20,24 Natriuretic peptides are known as antihypertensive hormones. They have natriuretic and diuretic effects, cause vasorelaxation, and have anti-proliferative, anti-inflammatory and anti-hypertrophic effects (Figure 2).^24,25 NPs are autocrine and paracrine mediators which are released by cardiomyocytes, endothelial cells, and fibroblasts and regulate vital physiological functions in the cardiovascular system.²⁶ They control of inflammation, angiogenesis, smooth muscle and endothelial cell proliferation, atherosclerosis, cardiomyocyte contractility, hypertrophy, and fibrosis.²⁶ ANP causes vasodilation of the coronary arteries.²⁷ ANP. BNP, and DNP (a 38 amino acid peptide) stimulate NPR-A, whereas CNP exhibits selectivity to NPR-B.¹⁰ ANP, BNP, CNP and DNP activate NPR-C.¹⁰ The receptors for NPs are represented by 3 types: NPR-A, NPR-B, and NPR-C. NPR-A is a dimer that interacts with PNP, MNP, DNP and is guanylyl cyclase; NPR-B is a dimer that interacts only with CNP and is also guanylyl cyclase.¹⁰ NPR-C is also a dimer, it interacts with all NPs. NPR-C is coupled to the G_i-protein, which allows it to inhibit adenylyl cyclase and, accordingly, reduce cAMP synthesis.¹⁰ ANP, BNP, and DNP (a 38 amino acid peptide) stimulate preferentially NPR-A, and CNP exhibits selectivity for NPR-B.¹⁰ ANP, BNP, CNP, and DNP activate NPR-C (Figure 3).¹⁰ cANP (4-23) is the selective agonist NHR-C.²⁸ mRNA of all 3 receptors was found in the heart, the most pronounced expression was shown for NPR-C.²⁹ NPRs are expressed in the atria to a greater extent than in the ventricles.¹⁰ The ventricular guanylyl cyclase activity and the cGMP levels were decreased by 96% and 87%, respectively, in Npr1^-/- mice.³⁰ Endothelial-specific deletion of Nppc, which encodes CNP, leads to endothelial dysfunction, hypertension, atherosclerosis, and aneurysm.³¹ Administration of NPR-C agonists promotes vasorelaxation of isolated arteries and a reduction in blood pressure (BP) in wild-type animals that is diminished in mice lacking NPR-C.³¹ Intravital microscopy studies showed that CNP increases the diameter of arterioles and capillaries.³² The vasodilatatory effect of CNP were preserved in mice with endothelial NPR-B deletion, but abolished in mice lacking NPR-B in microcirculatory SMCs and pericytes.³² Endothelium-specific deletion of CNP (ecCNP^-/-), resulted in impaired coronary responsiveness to endothelium-dependent- and flow-mediated-dilatation in mice.³³

Figure 2.

The main cardiovascular effects of natriuretic peptides (NPs).

Figure 3.

Intracellular signaling pathway for the realization of the cardioprotective effect in activation of natriuretic receptors. AC, adenylate cyclase; Akt, protein kinase B; AMPK, cyclic adenosine monophosphateactivated kinase; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; CNP, C-type natriuretic peptide; DNP, Dendroaspis natriuretic peptide; ERK1/2, extracellular regulated kinase; Gi, inhibitory G protein; GC, guanylate cyclase; GTP, guanosine triphosphate; HO1, hemeoxygenase-1; MEK(MAPK), mitogen-activated protein kinase; mitoKATP, mitochondrial ATP-dependent potassium channel; mPTP, mitochondrial permeability transition pore; NO, nitric oxide; NOS, nitric oxide synthase; NPR-A, natriuretic peptide receptor A; NPR-B, natriuretic peptide receptor B; NPR-C, natriuretic peptide receptor C; PDE3, phosphodiesterase 3; PI3K, phosphoinositide-3-kinase; PKA, protein kinase A; PKC, protein kinase C; PKG, protein kinase G; PPARγ, peroxisome proliferator-activated receptor γ; sarcoKATP, sarcolemmal ATPdependent potassium channel. On the arrows «+» shows activation, and «-» blocking the pathways.

In 2000, corin was discovered, a transmembrane cardiac serine protease, which converts pro-ANP to ANP.³⁴ Corin was found in cardiomyocytes, atriums, ventricles of the human heart.³⁵ Proprotein convertase subtilisin/kexin-6 (PCSK6, also named PACE4) is enzyme converting pro-corin to corin,³⁶ and is expressed in the atrium and left ventricle of the heart.³⁷ Furin is another enzyme which converts pro-NPs into active NPs.³⁸ It is also expressed in the myocardium.³⁸ NPs are metabolized by the neutral endopeptidase neprilysin, which is expressed in many organs and tissues.³⁹ It is believed that selective neprilysin inhibitors may be effective in treatment of hypertension and heart failure (HF).³⁹

An increase in the secretion of NPs by cardiomyocytes occurs in response to an increase in the intracellular concentration of Ca²⁺.⁴⁰ The key role in this process is played by calmodulin kinase II.⁴⁰ In addition, it was found that infusions of norepinephrine evoked a 7-fold increase in the plasma ANP level in rabbits.⁴¹ However, stimulation of right inferior cervical ganglion in vagotomized, anesthetized rabbits had no effect on the ANP level.⁴¹ Norepinephrine and epinephrine also stimulate BNP release from the isolated human atrial myocardium.⁴² Adenosine α₁ and α₂-adrenergic receptor (AR) agonists stimulate ANP secretion, whereas β₁-AR stimulation inhibits ANP release.⁴³ BNP synthesis and secretion of by isolated cardiomyocytes is enhanced in response to hypoxia.^44,45 Chronic hypoxia causes an increase in ANP level in plasma of rats.⁴⁶ There are many stimuli that are known to increase gene expression and/or to trigger the release of CNP are pertinent to cardiovascular diseases, including shear stress, inflammatory cytokines such as tumor necrosis factor-α, interleukin 1β, transforming growth factor-β, and bacterial lipopolysaccharide.²⁶ It was found that the expression of ANP, NPR-A, and NPR-C is increased in endothelial NO-synthase deficient mice (eNOS^-/-).⁴⁷ This may be a response to an increase in BP in these mice. However, an increase in NP synthesis can also be observed in the absence of an increase in BP, for example, in mice after bilateral renal ischemia-reperfusion.⁴⁸ A decrease in eNOS activity in the myocardium, cardiac hypertrophy, and an increase in BNP synthesis in the myocardium were observed 4 to 5 months after renal ischemia-reperfusion in mice.⁴⁸ To finally resolve the question of the role of NO in the regulation of NP synthesis, studies on isolated cardiomyocytes are necessary. The synthesis and secretion of BNP by isolated cardiomyocytes is enhanced in response to hypoxia.^44,45 Chronic hypoxia causes an increase in ANP level in plasma of rats.⁴⁶

Data From Experimental Studies

Infarct-Reducing Effect of Natriuretic Peptides

In a study performed on the isolated perfused rat heart, using coronary artery occlusion (35 min) and reperfusion (2 h), BNP (10^-8 M) contributed to a striking reduction in infarct size by about 50% (Table 1).⁴⁹ This BNP effect was accompanied by a 2.5-fold increase in the cGMP level. Moreover, it was found that the inhibitor of mitochondrial ATP-sensitive K⁺ channel (mitoK_ATP channel) 5-hydroxydecanoate eliminates the cardioprotective effect of BNP. It is well known that cGMP and mitoK_ATP channel opening protect the heart from ischemic and reperfusion injuries.⁵⁰ Consequently, it can be assumed that the infarction-limiting effect of BNP is associated with mitoK_ATP channel opening in cardiomyocytes and an increase in the cGMP level in the myocardium. In a study performed in the isolated perfused rat hearts, using coronary artery occlusion (20 min) and reperfusion (120 min) to induce ischemia-reperfusion damage, synthetic human α-ANP (carperitide) reduced the infarct size/area at risk (IS/AAR) ratio by 40% (Table 1).⁵¹ Later, in experiments on the isolated heart, the infarct-reducing effect of cANP4-23 and CNP was shown (Table 1).¹⁸ In another study in the isolated perfused rat heart, BNP added to the perfusion solution 5 min before reperfusion caused a decrease in the IS/AAR ratio by 44% after local ischemia (35 min), followed by reperfusion (120 min) (Table 1).⁵² In the latter study, it was found that the inhibition of NO synthase, blockade of sarcolemmal K_ATP channel (sarcK_ATP channel), and blockade of the mitoK_ATP channel led to the elimination of the infarction-reducing effect of BNP. The investigators concluded that the cardioprotective effect of BNP is associated with K_ATP channel opening and NO-synthase activation.

Table 1.

The Infarct-Reducing and Cytoprotective Effects of Natriuretic Peptides In Vitro.

Peptides	Animals	Before ischemia; after ischemia; hypoxia/reoxygenation of cardiomyocytes	Effect	Authors
BNP	Rat	Before ischemia	IS/AAR ↓	D’Souza S.P. et al., 2003
Carperitide	Rat	Before ischemia	IS/AAR ↓	Okawa H. et al., 2003
cANP4-23, CNP	Rat	Before ischemia	IS/AAR ↓	Hobbs A. et al., 2004
BNP	Rat	After ischemia	IS/AAR ↓	Burley D.S. et al., 2007
ANP	Rat	After ischemia	IS/AAR ↓	Yang XM et al., 2006
BNP	Rat	Reoxygenation of cardiomyocytes	Cell apoptosis ↓	Sun Y et al., 2009;
ANP	Rat	After ischemia	Contractility ↑	Fujii Y et al., 2012;
BNP	Rat	After ischemia	IS/AAR ↓	Breivik L et al., 2015

Note. IS/AAR, infarct size/area at risk.

NPs exhibit cardioprotective properties not only in vitro, but also in vivo. Coronary artery occlusion (90 min) and reperfusion (6 h) were induced in dogs (Table 2).⁵³ Carperitide (human α-ANP) was administered (0.2 μg/kg/min) 15 min after coronary artery occlusion and infusion was continued until the end of reperfusion. Carperitide treatment contributed to a 84% reduction in infarct size. It was found that intravenous bolus administration of rabbit ANP (2.5 μg/kg) 15 min before ischemia induced a 84% reduction in the IS/AAR ratio in rabbits with coronary occlusion (90 min) and reperfusion (3 h) (Table 2).⁵⁴ In a dog model, myocardial ischemia was simulated by reducing blood flow in the left anterior descending coronary artery by 66% (Table 2).²⁷ Carperitide was infused (0.1 μg/kg/min) intracoronary during cardiac ischemia. It turned out that carperitide improved contractility of the heart and increased coronary blood flow by enhancing cGMP synthesis. HS-142 -1, a NPR antagonist, eliminated the protective effects of carperitide. In addition, the NO-synthase (NOS) inhibitor L-NAME eliminated carperitide’s protective effects. Carperitide reduced the IS/AAR ratio, which was determined after ischemia (90 min) and reperfusion. These data indicate that carperitide increases coronary blood flow and cardiac tolerance to ischemia/reperfusion.²⁷ In another study, BNP was administered to rats with permanent coronary occlusion for 28 days (Table 3).⁵⁵ Half of the rats in the untreated infarction control group died during this period. At the end of the experiment, the left ventricular (LV) weight increased by 28%, and left ventricular end-diastolic pressure (LV EDP) increased 5-fold in untreated infarction control rats. Chronic BNP treatment reduced EDP by 46%, decreased LV weight by 17%, and increased the survival of rats with myocardial infarction. The authors concluded that chronic administration of BNP increases survival of rats with permanent coronary occlusion and prevents postinfarction remodeling of the heart.²⁷ A study performed in ANP-null mice with coronary artery occlusion (30 min) and reperfusion (120 min) showed that lack of endogenous ANP aggravates adverse cardiac remodeling induced by pressure overload in mice.⁵⁶ Mice lacking NPR-A gene Npr1 (Npr^-/-) have marked cardiac hypertrophy and fibrosis disproportionate to their increased blood pressure.⁵⁷ Recently, a study has been published in cardiomyocyte (cmCNP^-/-), endothelium (ecCNP^-/-), and fibroblast (fbCNP^-/-)-specific CNP knockout mice, as well as global (NPR)-B^-/-, and NPR-C^-/- knockout mice.³³ Global ischemia of the isolated murine heart evoked an increase in infarct size and diminished functional recovery in cmCNP^-/- and NPR-C^-/-, but not in ecCNP^-/- mice vs. wild-type controls. The cardiac phenotype of cmCNP^-/-, fbCNP^-/-, and NPR-C^-/- (but not ecCNP^-/- or NPR-B^-/-) mice was more sensitive to pressure overload- and sympathetic hyperactivation-induced HF compared with wild-type mice.³³

Table 2.

The Infarct-Reducing Effect of Natriuretic Peptides In Vivo.

Peptide	Animals	Before ischemia; after ischemia	Effect	Authors
Carperitide	Dog	After ischemia	IS/AAR ↓	Takagi G. et al., 2000
Carperitide	Rabbit	Before ischemia	IS/AAR ↓	Zhang W.W. et al., 2008
BNP	Rabbit	After ischemia	IS/AAR ↓	Wu B et al., 2009
Carperitide	Dog	During ischemia	IS/AAR ↓	Asanuma H. et al., 2014
ANP	Rat	Before ischemia	IS/AAR No	Charan K et al., 2016
BNP	Rat	After ischemia	IS/AAR ↓	Hu G et al., 2014
BNP	Mouse	After ischemia	IS/AAR ↓	Tourki B et al., 2019

Note. IS/AAR, infarct size/area at risk.

Table 3.

Natriuretic Peptides Prevent Post-Infarction Cardiac Remodeling.

Peptide	Animals	Duration of administration after coronary artery occlusion	Effect	Authors
CNP	Rat	14 days	Collagen ↓ LV dilatation ↓ Contractility ↑	Soeki T et al., 2005
CNP overexpression	Mouse	28 days	LV hypertrophy ↓	Wang Y et al., 2007
BNP	Rat	8 weeks	Survival ↑ Contractility ↑	Pan Y. et al., 2011
BNP	Rat	14 days	Cardiac hypertrophy↓ Collagen ↓	He J et al., 2009
CNP	Mouse	2 weeks	Contractility ↑ Cardiac hypertrophy↓	Izumiya Y et al., 2012
BNP	Mouse	Single injection	Collagen ↓ Inflammation ↓	Tourki B et al., 2019

Note. LV, left ventricle.

The use of neprilysin inhibitors may be another approach to prevent post-infarction cardiac remodeling. It was shown that the neprilysin inhibitor LCZ696 can increase the survival of mice with experimental myocardial infarction treated for 28 days.⁵⁸ Consequently, NPs inhibit adverse cardiac remodeling in different species and experimental settings. However, it remains unclear which NPRs are involved in the antifibrotic effects of NPs. It is well known that transforming growth factor-β1 (TGF-ß1) plays an important role in cardiac fibrosis. In isolated fibroblasts, knockdown of NPR-C resulted in a marked reduction of collagen in murine atrial and ventricular fibroblasts/myofibroblasts in response to TGF-ß1 stimulation.⁵⁹ There was a marked reduction in atrial fibrosis gene expression in mice with NPR-C knockdown and transverse aortic constriction (TAC) compared to wild-type mice with TAC. These data indicate that NPR-C may play a beneficial role in prevention of cardiac remodeling.

One of the most widespread diseases of our time is diabetes mellitus (DM), which exacerbates the course of cardiovascular diseases. Therefore, it was important to find out how it affects the cardioprotective effect of ANP. The study was performed in rats with alloxan-induced diabetes,⁶⁰ and showed that ANP did not have an infarct-limiting effect in rats with diabetes (Table 2). It should be noted that alloxan treatment mimics type 1 diabetes, while type 2 diabetes prevails among patients with diabetes. Therefore, the latter study does not rule out that ANP may have cardioprotective effects in patients with type 2 diabetes. It has been suggested that BNP may be involved in the pathogenesis of diabetic cardiomyopathy.⁶¹ There are data that diabetes promotes an increase in ANP and BNP expression in the heart of streptozotocin-induced diabetic rats.⁶² However, it is unclear whether enhancement of ANP and BNP expression is protective or aggravates diabetic cardiomyopathy. No differences were found between patients with acute heart failure with diabetes and without in terms of the serum BNP level.⁶³ It is established that the sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular mortality and re-hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D).^64,65 In addition, the SGLT2 inhibitor empagliflozin prevented post-infarction cardiac remodeling in rats.⁶⁶ However, in a randomized, placebo-controlled, double-blind, multicentre pilot study including 80 acute HF patients with and without diabetes a positive effect of empagliflozin on HF and on plasma Pro-BNP levels could not be detected.⁶⁷ In contrast, in a multicentre, parallel-group phase IIA study including 125 patients with T2DM and HF it was found that the combined SGLT1/SGLT2 inhibitor licogliflozin reduced the plasma NT-proBNP level vs placebo, whereas empagliflozin had no effect on the NT-proBNP level.⁶⁸ The EMMY trial is designed to finally clarify the appropriateness of empagliflozin for the treatment of HF.⁶⁹

It has been well established that NPs can prevent cardiac reperfusion injury even when they are used after the ischemic injury of the heart has already occurred.^52,70

-74 Isolated rabbit hearts were subjected to a 30-min coronary artery occlusion, followed by a 120-min reperfusion.⁷⁰ When ANP was added to the perfusion solution 5 min before reperfusion, it caused a decrease in the IS/AAR ratio by 60%. Similarly, in studies performed in isolated perfused rat hearts, BNP and ANP prevented cardiac reperfusion injury after coronary occlusion and improved left ventricular function after cardiac global ischemia-reperfusion when added to the perfusion solution (Table 1).^52,71,73,75 In concordance with the ex vivo studies, in vivo studies in rats subjected to coronary occlusion (30 min) and reperfusion (4 h) showed that infusion of BNP (0.03 μg/kg min, i.v.), starting 15 min before reperfusion until the end of reperfusion, decreased the IS/AAR ratio by approximately 50%.⁷² In line with the latter study, it was shown that intraperitoneal administration of BNP 5 min before reperfusion contributed to a decrease in the IS/AAR ratio by an average of 50%.⁷¹

Natriuretic Peptides and Postinfarction Myocardial Remodeling

There is good evidence that NP treatment has beneficial effects on postinfarction cardiac remodeling. For example, it was found that continuous CNP infusion (0.1 µg/kg/min) by osmotic mini-pump during 2 weeks after permanent coronary artery occlusion prevented post-infarction myocardial remodeling (Table 3).⁷⁶ Furthermore, Wang and coworkers showed that cardiomyocyte-specific CNP overexpression had no effect on infarct size in mice, but prevented both left and right ventricular hypertrophy after coronary artery occlusion (Table 3).⁷⁷ When rats with permanent coronary occlusion were injected intravenously with BNP (15 μg/kg/day) over 8 weeks, BNP treatment prevented cardiac hypertrophy and a decline in ejection fraction, decreased the plasma angiotensin II level, and decreased collagen content in the myocardium (Table 3).⁷⁸ In an experiment in which angiotensin II was continuously infused subcutaneously into mice by osmotic minipump during 2 weeks, co-infusion of CNP prevented angiotensin II-induced myocardial hypertrophy, cardiomyocyte hypertrophy, interstitial fibrosis (Table 3).⁷⁹ In addition, CNP decreased angiotesin II-induced cardiac superoxide generation by myocardial tissue.⁷⁹ The latter authors concluded that CNP suppresses angiotensin-induced cardiac hypertrophy by inhibition of superoxide production.

It is well known that one of the signs of post-infarction remodeling in the heart is myocardial fibrosis. In this context it was found that a single injection of BNP before the restoration of coronary blood flow reduced the myocardial collagen level by about 30%, 14 days after reperfusion (Table 3).⁷⁴ It is well known that inflammation plays an important role in ischemia/reperfusion injury of the myocardium.^80,81 Therefore, it has been suggested that the cardioprotective effect of BNP during reperfusion may be a consequence of the limitation of leukocyte infiltration in the infarcted area. Indeed, it turned out that after 2 days of cardiac reperfusion, the number of leukocytes in the infarction zone in BNP-treated rats decreased by 30% (Table 2).⁷⁴ These data indicate that BNP prevents cardiac reperfusion injury, and reduces the manifestations of postischemic fibrosis of the heart, possibly through the limitation of leukocyte infiltration into the necrosis zone. The cardioprotective effect of BNP is long-term in nature and persists for at least 14 days.

After genetic knockout of the Npr1 gene encoding NPR-A in mice, blood pressure rises in mice and cardiac hypertrophy develops.²⁴ BP was elevated by 41 mm Hg in Npr1^-/- mice, together with 60% increased heart weight/body weight ratio and cardiomyocyte hypertrophy.³⁰ These data indicate that endogenous NPs can prevent the development of cardiac hypertrophy. Furthermore, it was demonstrated that cardiac-specific disturbance of NPR-A activity accentuates adverse cardiac remodeling and mortality in response to pressure overload in mice.⁸² In contrast, subcutaneous infusion of CD-NP (synthetic NP) during 2 weeks prevents left ventricular fibrosis and decreased circulating aldosterone levels in rats with unilateral nephrectomy.⁸³ Another study of the same group examined the role of corin and furin in atrial fibrosis in dogs with rapid right ventricular pacing for 10 days.⁸⁴ In the left atria, corin mRNA and protein expression were lower, whereas furin mRNA and protein expression were higher than normal.³⁸ Moreover, it was demonstrated that the failing human left ventricle is characterized by increased fibrosis and reduced CNP gene expression.⁸⁴

Natriuretic Peptides, Apoptosis, Pyroptosis and Autophagy

In 2009, Wu et al demonstrated that BNP can protect the heart from ischemia-reperfusion injury by inhibition of apoptosis.⁸⁵ The latter study was performed in rabbits subjected to coronary occlusion (45 min) and reperfusion (3 h). BNP infusion was started 5 min before reperfusion and continued throughout reperfusion. BNP infusion reduced infarct size by 44% (Table 2), and the number of apoptotic cells (TUNEL-positive cardiomyocytes) in the heart by approximately 60%.⁸⁵ At the same time, BNP increased protein expression of anti-apoptotic Bcl-2, reduced pro-apoptotic Bax protein expression, and prevented caspase-3 activation. Similar data were obtained by other researchers.⁸⁶ BNP was also shown to prevent hypoxia-induced apoptosis of neonatal rat cardiomyocytes.⁸⁷ BNP prevented the fall of Δψ in mitochondria, and decreased ROS generation in cardiomyocytes. In addition, BNP increased Bcl-2, decreased the Bax level, and decreased the Smac/DIABLO ratio.⁸⁷ The PI3 kinase inhibitor wortmannin abolished the anti-apoptotic effect of BNP.⁵⁸ Furthermore, is was reported that BNP prevented apoptosis of H9c2 cardiomyoblasts under hypoxia/reoxygenation conditions.⁸⁸ Pretreatment with the selective cGMP-dependent protein kinase G (PKG) inhibitor KT-5823 significantly weakened the anti-apoptotic effect of BNP.⁸⁸ In contrast, some experiments suggested that BNP can actually enhance the apoptosis of neonatal rat cardiomyocytes in conditions of moderate hypoxia and increase caspase-3 activity.⁸⁹

It is well known that caspase-1, interleukin-1β (IL-1β) and inflammasome formation are involved in the development of pyroptosis.⁹⁰ In this context, it has been shown that ANP and BNP are able to suppress lipopolysaccharide-induced IL-1β release from human monocytes, and to inhibit inflammasome formation and caspase-1 activation in monocytes.^91,92 Consequently, ANP and BNP can suppress pyroptosis of monocytes. Whether NPs might inhibit pyroptosis of cardiomyocytes is currently unknown.

It is well known that mTOR (mammalian target of rapamycin) kinase is a strong inhibitor of autophagy.⁹³ Therefore, using the mTOR inhibitor rapamycin, it is possible to indirectly estimate a role of autophagy in a particular process. It was found that BNP inhibits mTORC1 in adipocytes.⁹⁴ Moreover, pretreatment with rapamycin abolished the infarct-limiting effect of BNP-mediated postconditioning.⁷² These data indirectly indicate that the infarct-reducing effect of natriuretic peptides may depend on modulation of autophagy. However, these indirect findings require confirmation.

Natriuretic Peptides and ROS

It is well known that a high content of reactive oxygen species (ROS) induces cardiomyocyte injury, whereas in small concentrations ROS can function as intracellular signaling molecules.^95,96 Therefore, it was important to find out how natriuretic peptides affect the ROS level in cardiomyocytes. Angiotensin II was infused subcutaneously into mice using an osmotic minipump over 2 weeks to stimulate ROS production in the heart in vivo.⁷⁹ Co-administration of CNP decreased angiotensin II-induced cardiac hypertrophy and superoxide production in myocardial tissue. This effect was accompanied by suppression of NADPH-oxidase expression.⁷⁹ These data indicate that CNP attenuated angiotensin II-induced cardiac hypertrophy and fibrosis, the effect which was associated with reduced superoxide radical production. Similarly, treatment of adult spontaneously hypertensive rats (SHRs) with an ANP derivative for 2 weeks attenuated hypertension, and restored the impaired vasorelaxation toward control level.²⁵ In addition, ANP reduced the superoxide anion and peroxynitrite levels, and decreased NADPH-oxidase activity in aorta, heart, and kidney of SHRs. The latter authors used C-atrial natriuretic peptide (cANP)4-23, a peptide with selectivity to NPR-C. This fact allowed them to conclude that selective stimulation of NPR-C without an increase in the cGMP level can prevent the development of hypertension and an increase in ROS production.²⁵ Along similar lines, it was shown that ANP reduced lipopolysaccharide-induced intracellular ROS production in endothelial cells,⁹⁷ that BNP inhibits angiotensin II-induced ROS production in pulmonary arterial smooth muscle cells⁶⁷ and postnatal ductus arteriosus smooth muscle cells,⁹⁸ and that ANP prevents isoproterenol-induced mitochondrial ROS production in failing cardiomyocytes.⁹⁹ In 2018, Jain A et al demonstrated that cANP4-23 inhibits superoxide generation and NADPH oxidase activity in vascular smooth muscle cells (VSMC) isolated from SHRs and Wistar rats.¹⁰⁰ The ability of cANP4-23 to inhibit the enhanced oxidative stress in VSMC isolated from SHRs was confirmed in other studies.^101,102

High frequency stimulation increased ANP secretion in atria of both diabetic and sham rats. Interestingly, the ROS scavenger N-acetyl-cysteine (NAC) attenuated but did not abolish ANP secretion, whereas the NADPH inhibitor apocynin had no effect in sham rat atria. However, both apocynin and NAC completely inhibited ANP secretion in diabetic rat atria.¹⁰³ These data indicate that ROS can trigger ANP secretion especially in diabetic rats.

Natriuretic peptides can not only inhibit ROS production but also stimulate ROS generation in some experimental settings. In this context, it was demonstrated that CNP enhances NADPH-depended ROS production in rat aorta homogenates.¹⁰⁴ It is well known that ROS play a role as intracellular messengers in cardioprotective pre- and post-conditioning effects.¹⁰⁵ For example, the infarct-reducing effect of bradykinin is mediated via ROS generation in the myocardium.¹⁰⁶ Although the majority of studies suggest the inhibitory effect of NPs on ROS production in the strained heart, the exact role of the modulation of ROS production in the infarct-limiting effect of NPs is currently not known.

In conclusion, there is solid evidence from experimental studies that natriuretic peptides limit infarct size, increase survival of animals after experimental myocardial infarction, prevent cardiac reperfusion injury, have anti-inflammatory effects, and prevent post-infarction remodeling of the heart. In addition, it was established that BNP prevents hypoxia-induced apoptosis in cardiomyocytes. Indirect evidence suggests that natriuretic peptides may inhibit pyroptosis and may stimulate autophagy. Currently, there is only little information on how natriuretic peptides affect necroptosis, autophagy and pyroptosis of cardiomyocytes under conditions of hypoxia/reoxygenation. Taken together, the findings from experimental studies strongly suggest that natriuretic peptides or NPR receptor agonists may be useful in the treatment of myocardial infarction. Thus, most studies show that natriuretic peptides inhibit ROS production in cardiomyocytes, aorta, heart, kidney and VSMC.

Data From Clinical Studies

Two multicenter, prospective, randomized, blind, placebo-controlled trials included AMI patients who were given intravenous infusion of placebo or ANP (0.025 µg/kg/min) 3 days after hospitalization (Table 4).¹⁰⁷ Infarct size was estimated indirectly by the creatine kinase (CK) level in the blood. It turned out that the CK level was lower in patients who were injected with ANP. ANP treatment reduced infarct size by 14.7%. Six to 12 months after AMI, the LV ejection fraction (LV EF) was greater in patients who were injected with ANP. In 2015, the results of a study in patients with ST-segment elevation myocardial infarction (STEMI) and PCI were published (Table 4).¹⁰⁸ BNP was first administered intravenously by a bolus (1.5 μg/kg) before PCI, and then 0.0075 μg/ kg/min was infused intravenously for 120 hours. The infarction was estimated indirectly by the level of the serum markers of cardiomyocyte necrosis, troponin I and CK-MB. Echocardiography was performed 7 days later and 6 months after myocardial infarction. The serum troponin I and CK-MB levels were lower in patients who were administered BNP compared with the control group (nitroglycerin infusion). Although there were no differences between these groups in LV EF after 7 days, LV EF was higher in patients who were infused with BNP, 6 months after myocardial infarction. The authors concluded that intravenous administration of BNP contributes to limit the size of myocardial infarction and to inhibit postinfarction remodeling of the heart.¹⁰⁸

Table 4.

Natriuretic Peptides in Treatment of Myocardial Infarction.

Peptide	Duration of administration after AMI	Effect	Authors
ANP	24 hours	Cardiac contractility ↑ LV dilation ↓	Hayashi M. et al., 2001
ANP	7 days	Cardiac contractility ↑	Kuga H. et al., 2003
ANP	3 days	CK level ↓ Cardiac contractility ↑	Kitakaze M. et al., 2007
BNP	120 hours	Troponin I ↓, CK-MB ↓ Cardiac contractility ↑	Li S. et al., 2015
Carperitide	3 days	Mortality No effect	Isogai T et al., 2016

Note. CK-MB, creatine kinase, LV, left ventricle.

In a placebo-controlled study including 133 patients with coronary artery bypass grafting and cardioplegic cardiac arrest, which is essentially cardiac ischemia, human ANP was infused with 0.02 μg/kg/min immediately after the initiation of cardiopulmonary bypass.¹⁰⁹ The incidence of postoperative complications was lower in patients who were infused with ANP. In addition, LVEF in the postoperative period was higher after administration of ANP, and circulating BNP levels as an indicator of heart failure were lower.¹⁰⁹ However, there was no difference between the groups in mortality rate in the first year post-operatively.

There is also evidence that ANP has beneficial effects on postinfarction remodeling of the heart. ANP was infused continuously (0.025 μg/kg/min) for 24 hours in patients with STEMI and PCI (Table 4).¹¹⁰ The control group included patients with AMI who were injected nitroglycerin. One month after AMI, LVEF was higher in patients who were injected with ANP. In addition, patients treated with ANP had less LV dilatation, and lower plasma levels of aldosterone, angiotensin II, and endothelin-1. The authors concluded that ANP inhibits postinfarction remodeling of the heart.¹¹⁰ In another study, human ANP was infused continuously (0.025 μg/kg/min) for 7 days in patients with STEMI and PCI (Table 4).¹¹¹ In addition, ANP was administered intracoronary during PCI. Six months after myocardial infarction, the LV end-diastolic volume (LV EDV) was lower, and LV EF was higher in patients who were injected with ANP. These findings suggest that ANP may prevent postinfarction remodeling of the heart.

The most important indicator of the efficacy of drug therapy in any disease is the reduction in mortality. In 2016, the results of a multicenter study performed in Japan were published.¹¹² The study included 60,592 patients with AMI and PCI (81,89 ANP group, 52,403 control group) from 850 hospitals. Investigators were not able to detect a significant difference in 30-day mortality between the ANP (carperitide) and control group (3.4% vs. 3.8%, respectively). Carperitide was administered on the second day after PCI. Perhaps for this reason, the positive effect of carperitide could not be detected. In addition, this study was not the randomized, blind, and placebo-controlled trial.¹¹² Hence, it is unclear whether a study by Isogai and coworkers can provide conclusive evidence of a lacking effect of ANP on mortality after AMI (Table 4).

Thus, natriuretic peptides increase tolerance of the human heart to ischemia/reperfusion and have the infarct-limited effect in patients with AMI. ANP prevents post-infarction remodeling of the heart.

Natriuretic Peptides as Predictors of Mortality

It was reported that an increase in BNP levels in blood of cardiosurgical patients before cardiopulmonary bypass, which is accompanied by total cardiac ischemia, may predict death of patients.¹¹³ Similar data were obtained regarding an increase in the N-terminal pro BNP (NT-ProBNP) level in the period preceding cardiac surgery.¹¹⁴ It was shown that the elevated NT-proBNP level during admission of patients with AMI was associated with a higher risk of mortality.¹¹⁵ An increase in the N-terminal pro-BNP level predicts in-hospital mortality in patients with heart failure.¹¹⁶ Based on these data, it may be concluded that endogenous NPs actually exacerbate ischemia/reperfusion cardiac injury. However, it has to be considered that increased circulating levels of BNP and NT-proBNP are markers of pre-existent cardiac hypertrophy and heart failure. ANP and BNP are powerful clinical markers of cardiac hypertrophy and cardiac dysfunction.⁴⁰ Hence, the abovementioned associations between elevated circulating levels of endogenous BNP and negative outcome do not allow any firm conclusions about the potential therapeutic efficacy of NPs to limit ischemia/reperfusion injury in the heart. In our opinion, increasing levels of BNP and NT-proBNP is a protective response to extreme effects such as AMI and surgery. Indeed, there is evidence that the plasma ANP level increases in humans by 3-fold during stress exposure.¹¹⁷ We believe that NPs protect the heart from adverse effects.

Potential Mechanisms Underlying the Infarct-Reducing and Anti-Fibrotic Effects of Natriuretic Peptides

Anti-Inflammatory Effect of Natriuretic Peptides

It was found that inflammation plays an important role in reperfusion injury to the heart and the development of myocardial fibrosis.^118,119 Therefore, it was important to evaluate the effect of natriuretic peptides on inflammation during ischemia/reperfusion of the heart. It was found that ANP limits polymorphonuclear neutrophils adhesion to hypoxic endothelial cells.¹²⁰ It has been found that ANP may protect the heart from angiotensin II-induced myocardial remodeling by attenuating inflammation.¹²¹ Pretreatment with ANP reduced TNF-α-induced expression of monocyte chemoattractant protein-1 (MCP-1) by human umbilical vein endothelial cells.¹²² It has been established that ANP prevents an increase in the serum tumor necrosis factor-α (TNF-α) level in mice after bacterial lipopolysaccharide administration but had no effect on TNF-α expression in the mouse heart.¹²³ However, there are data that BNP had no effect on TNF-α release from macrophages.¹²⁴

It was demonstrated that plasma concentrations of proinflammatory cytokines TNF-α, interleukin-6 (IL-6), and interleukin-1 (IL-1) is elevated in Npr1-/- mice in comparison with wild-type mice.¹²⁵ It was shown that ameliorates lipopolysaccharide-induced acute lung injury and reduced the serum IL-1β and IL-6 levels in rats.¹²⁶ Investigators showed that oleic acid-induced acute lung injury is associated with an increase in the TNF-α, IL-1β and IL-6 levels in rats.¹²⁷ Pretreatment with ANP prevented this elevation of the proinflammatory cytokines level. Other investigators showed that ANP prevents elevation of the serum TNF-α and IL-6 levels in dogs after lipopolysaccharide administration.¹²⁸ High mobility group box 1 protein (HMGB1) released by necrotic cells and stimulates proinflammatory cytokine production positively activated macrophages and monocytes.¹²⁹ BNP was administrated 15 min before cardiac reperfusion.⁷¹ Authors demonstrated that BNP decreases infarct size, reduces TNF-α, IL-6, HMGB1 content in myocardial tissue. It was established that intravenous administration of CNP (25 μg/kg) to rats with hemorrhagic shock prevents an increase in TNF-α, IL-1β and IL-6 content in the kidney.¹³⁰ Investigators found that CNP reduces secretion of MCP-1 and plasminogen activator inhibitor-1 (PAI-1) by cardiac fibroblasts.¹³¹ They suggest that a decrease in MCP-1 and PAI-1 secretion is involved in the antifibrotic effect of the peptide. It was demonstrated that CNP prevents ventricular hypertrophy in SHR and induces an anti-inflammatory and antifibrotic response in SHR.¹³² Other investigators also report on the anti-inflammatory effect of CNP.²⁶

Thus, a number of studies have shown that natriuretic peptides have the anti-inflammatory effect, reduce the inflammatory mediators’ level in the blood and tissues. However, it remains unclear to what extent the anti-inflammatory effect of these peptides is involved in their infarct-limiting and the antifibrotic effects.

Natriuretic Peptides, Angiotensin II, Aldosterone, Endothelin-1

It is well known that angiotensin II, endothelin-I, aldosterone are involved in the postinfarction adverse remodeling heart.^118,133 The AT₁ receptor antagonists contribute to a decrease in the IS/AAR ratio.^134,135 The endothelin receptor antagonists have the cardioprotective effect on coronary artery occlusion and reperfusion.¹³⁶ Therefore, it was important to evaluate how these peptides affect the angiotensin II and aldosterone levels. It was shown that ANP inhibits ACTH-stimulated aldosterone secretion in mice.¹³⁷ ANP infusion promoted a decrease in the plasma aldosterone and angiotensin II levels in patients with AMI.¹¹⁰ Angiotensin II-induced ventricular hypertrophy is suppressed in mice with BNP overexpression.¹³⁸ The plasma angiotensin II level increased 4-fold 8 weeks after the experimental myocardial infarction in rats. The course BNP administration led to a decrease in the angiotensin II level almost to normal value.⁷⁸ It was shown that the angiotensin II induces cardiac fibroblast proliferation and collagen synthesis by these cells.¹³⁹ ANP inhibited both effects of angiotensin II. siRNA inhibited NPR-A expression in isolated cardiac fibroblasts and eliminated the effects of ANP.¹³⁹ Consequently, NPR-A abolishes the effects of angiotensin II on the cell. In response to 21 days of transverse aortic constriction, NPR-1^-/- mice developed enhanced left ventricular hypertrophy, fibrosis and contractile dysfunction.¹⁴⁰ Pretreatment with the mineralocorticoid receptor (MR) selective antagonist eplerenone prevented cardiac hypertrophy. Authors demonstrated coimmunoprecipitation MRs and ANPs. Authors proposed that aldosterone can cause a conformational change of MR/NPR-A complex which was prevented by ANP.¹⁴⁰ We have already reported that long-term CNP infusion attenuates angiotensin II-induced cardiac superoxide production and myocardial remodeling.⁷⁹ It has been demonstrated that ANP may protect the heart from angiotensin II-induced myocardial remodeling by attenuating inflammation.¹²¹ It was demonstrated that ANP attenuated angiotensin II-induced aldosterone synthesis in a human adrenocortical cell line (NCI-H295 R).¹⁴¹

In 1993, Uemasu J et al demonstrated that ANP infusion induced a decrease in the plasma endothelin-1 level in men.¹⁴² Another group investigators found that ANP suppresses endothelin-1 gene expression and proliferation in cardiac fibroblasts.¹⁴³ Administration of ANP suppressed the plasma endothelin level in patients with AMI.¹¹⁰ Investigators established that in vitro, angiotensin II increased endothelin-1 expression in cardiac fibroblasts, which were reduced by ANP.¹²¹

Presented data showed that natriuretic peptides can suppress aldosterone, angiotensin II, endothelin-1 synthesize and secretion and inhibit the effects aldosterone, angiotensin II on the post-receptor level through intracellular signaling events.

Natriuretic Peptides, cAMP, cGMP, PKG

The cardiovascular effects of atrial natriuretic peptides are mediated through intracellular signaling mechanisms, the most important of which are cAMP and cGMP. It was demonstrated that cGMP and PKG provide cardiac tolerance to ischemia/reperfusion.¹⁴⁴ In 2006, Yang et al., found that the soluble guanylyl cyclase inhibitor ODQ eliminates the infarct limiting effect of ANP at cardiac reperfusion.⁷⁰ In 2010, Qvigstad et al found that CNP enhances β₁-adrenergic receptor mediated increase of cAMP levels in failing hearts through phosphodiesterase 3 (PDE-3) inhibition.¹⁴⁵ Investigators demonstrated that BNP increases the cAMP level in PC12 cells and induces protein kinase A (PKA) phosphorylation in these cells.^146,147 They showed that BNP inhibited phosphodiesterase type 3-mediated cAMP hydrolysis in PC12 cells. It can be assumed that NPs can increase in cAMP content in cells via inhibition of PDE3 that could be detrimental in heart failure due to an increase in adrenergic drive. Protein kinase G is involved in this effect of CNP. In 2014, Vellaichamy E et al demonstrated that in Npr1(-/-) mice the myocardial guanylyl cyclase activity and the cGMP level in the heart were reduced by 96% and 87%, respectively.³⁰ However, these indices were elevated by 2.8-fold and 3.8-fold, respectively, in Npr1(++/++) mice.³⁰ CNP increased cGMP and enhanced β1- and β2-AR-mediated inotropic and lusitropic responses, in non-failing and failing hearts.¹⁴⁸ BNP increased cGMP, but did not affect inotropic or lusitropic responses on the AR agonists, indicating different compartmentation of cGMP from different NPRs.¹⁴⁸ It has been shown that a low concentration of norepinephrine increases cAMP content in isolated left ventricular cardiomyocytes.¹⁴⁸ Consecutive addition of CNP induced a further increase in the cAMP level in cardiomyocytes. The authors suggest that this CNP effect is associated with increased cGMP-mediated phosphodiesterase (PDE) 3 inhibition by NPR-B receptor activation.¹⁴⁸

Thus, the presented data indicate that natriuretic peptides activate guanylyl cyclase, activate PKG and PKA, and reduce the PDE-3 activity (Figure 3). It is unclear which of these changes provide increased cardiac tolerance to ischemia/reperfusion. It is well known that the β₁-adrenergic receptor (β₁-AR) antagonists inhibit cAMP synthesis and enhance cardiac tolerance to ischemia/ reperfusion.¹⁴⁹ However, there is evidence that β₁-AR stimulation enhances tolerance of this organ to ischemia/reperfusion.¹⁵⁰

Natriuretic Peptides and Protein Kinases

It is well known that kinases play an important role in intracellular signaling and regulation of cardiac tolerance to ischemia/reperfusion.^105,151 So, it was established that the activation of a number of kinases (AMPK, PKC, PI3 K, Akt, ERK1/2, PKG) increases the resistance of the heart to ischemia and reperfusion.^105,151 At the same time, increased activity of glycogen synthase kinase 3β (GSK-3β) contributes to the occurrence of ischemic and reperfusion injury to the heart.^105,151 Inhibition of protein kinase C (PKC) contributed to the disappearance of the cardioprotective effect of carperitide.⁵¹ The hepatoprotective effect of cANP4-23 during hypoxia of liver is mediated via PKC-δ activation.¹⁵² There are evidence that ANP-induced endothelial cells proliferation in vitro is mediated via activation of PKG, PI3 K, Akt, ERK1/2.¹⁵³ In 2006, Yang et al. found that the soluble guanylyl cyclase inhibitor ODQ eliminates the infarct limiting effect of ANP at cardiac reperfusion.⁷⁰ It was demonstrated that wortmannin, a phosphatidylinositol-3-kinase (PI3 K) inhibitor, or PD98059, a MEK kinase and extracellular signal-regulated protein kinases (ERK1/2) inhibitor, also abolished the infarct-reducing effect of ANP at reperfusion of the heart.⁷⁰ Consequently, the cardioprotective effect of ANP is mediated via the activation of PI3 K, MEK/ERK (ERK1/2). It was found that cANP4-23 inhibits VSMC proliferation via MEK/PI3K/Akt pathway.¹⁵⁴ There are data that ANP prevents mitochondrial permeability transition (MPT) pore opening in cardiac H9c2 cells via inhibition GSK-3β and activation of PKG and PI3 K.¹⁵⁵ It was shown that the PI3 K inhibitor LY294002 completely abolished the cardioprotective effect of BNP at reperfusion of the heart.⁷¹ Investigators believe that PI3K/Akt signaling pathway is involved in anti-inflammatory effect of BNP.⁷¹ In addition, investigators demonstrated that BNP increases the phospho-Akt (activated) kinase level in the myocardium. These facts indicated that PI3 K and Akt are involved in the infarct-limiting effect of BNP during reperfusion. CNP induced Akt phosphorylation in endothelial cells.⁹⁷ Pretreatment with inhibitors of PI3 K, Akt, p70s6 k kinases (wortmannin, SH-6, rapamycin) completely eliminated the infarct-reducing effect of BNP at reperfusion of the heart.⁷² Authors concluded that the PI3K/Akt/p70s6 k pathway is involved in the protective effect BNP at reperfusion. In 2018, Zhang et al. demonstrated that BNP attenuates hypoxia-induced injury in H9c2 cardiomyocytes via stimulation of PI3K/Akt/mTOR pathway.¹⁵⁶ Investigators could established that long noncoding RNA EGOT is involved in activation of PI3K/Akt/mTOR pathway. It was found that CNP and cANP4-23 stimulates phosphorylation of AMP activated kinase a1 (AMPK) in tissue of isolated beating rat atria.¹⁵⁷ This effect of ANP and cANP4-23 was mediated via activation of PKG and G_i/o-proteins.

Consequently, the cardioprotective effect of natriuretic peptides is mediated via activation of AMPK, PKC, PI3 K, MEK/ERK (ERK1/2), p70s6 k, Akt and inhibition of GSK-3β (Figure 3).

Natriuretic Peptides and NO-Synthase

It is well known that NO-synthase is an important regulator of cardiac resistance to ischemia/reperfusion.¹⁴³ Investigators established that the infarct-reducing effect of BNP during reperfusion is mediated via NO-synthase.⁵² The NOS inhibitor L-NAME abolished the infarct-reducing effect of carperitide²⁷ and ANP.^51,60 In 2010, Caniffi C et al. demonstrated that cANP4-23, a selective NPR-C receptor agonist, increased NOS activity in the heart.¹⁵⁸ cANP4-23 had no effect on NOS isoforms expression. The inhibitors of inducible NOS (iNOS) and neuronal NOS (nNOS) did not affect CNP-induced NOS activity. Cardiovascular NOS response to ANP4-23 was reduced by the G_i-protein inhibitor pertussis toxin and the calmodulin inhibitor calmidazolium.¹⁵⁸ Authors concluded that cANP4-23 interacts with NPR-C and activate Ca-calmodulin dependent eNOS via G_i protein.

Consequently, NOS is involved in the cardioprotective effect of natriuretic peptides (Figure 3). However, it remains unclear how the signal is transmitted from natriuretic peptide receptors on sarcolemma to NOS and soluble guanylyl cyclase in cytoplasm of the cell.

Natriuretic Peptides, HO-1 and PPARγ

It is known that hemeoxygenase-1 (HO-1) promotes an increase in cardiac tolerance to ischemia/reperfusion.¹⁵¹ It has been established the stimulation of peroxisome proliferator-activated receptor γ (PPARγ) increases myocardial resistance to ischemia/reperfusion.¹⁵⁹ It was shown that CNP induced activation of HO-1 expression in HUVECs.⁶⁶ There is no data on the ability of natriuretic peptides to stimulate HO-1 expression in cardiomyocytes. It was shown that ANP activates PPARγ expression in the area at risk of the swine heart at ischemia/reperfusion.¹⁶⁰

The presented data indicate that HO-1 and PPARγ may be involved in the infarct-reducing effect of natriuretic peptides (Figure 3).

Natriuretic Peptides, K_ATP Channels and MPT Pore

It has been demonstrated that ATP-sensitive (K_ATP) channels opening promotes an increase in cardiac tolerance to ischemia/reperfusion.¹⁰⁵ Therefore, it was important to evaluate the role of these channels in the cardioprotective effect of natriuretic peptides. The blockade of mitochondrial K_ATP channel (mitoK_ATP) channel led to the disappearance of the cardioprotective effect of carperitide.⁵¹ An involvement of mitoK_ATP in the cardioprotective effect of BNP has been demonstrated in D’Souza’s study.⁴⁹ It has been shown that the mitoK_ATP inhibitor 5-hydroxydecanoate eliminated the infarct-sparing effect of ANP at cardiac reperfusion.⁷⁰ Investigators established that the infarct-reducing effect of BNP during reperfusion is mediated via mitoK_ATP and sarcolemmal K_ATP (sarcK_ATP) channel opening.⁵² In 2014, Baxter’s group demonstrated that cardioprotective effect of ANP, BNP and cANP4-23 is mediated via sarcK_ATP channel opening.¹⁶¹

It has been established that MPT pore plays an important role in the cardioprotective effect of pre- and postconditioning.¹⁰⁵ MPT pore opining induces apoptosis of cardiomyocytes, MPT pore closing prevents ischemic/reperfusion injury of the heart.¹⁶² It has been shown that the cardioprotective effect of BNP at cardiac reperfusion is mediated via MPT pore closing.⁷³ There are data that ANP prevents MPT pore opening in H9c2 cardiomyoblasts.¹⁵⁵ The presented data are indirect evidence that natriuretic peptides exhibit the anti-apoptotic effect.

Consequently, the cardioprotective effect of natriuretic peptides is mediated via sarcK_ATP channel and mitoK_ATP channel opening. The cardioprotective effect of BNP is mediated via MPT pore closing (Figure 3).

Natriuretic Peptides and TGF-β1

It was found that transforming growth factor-β1 (TGF-β1) plays an important role in the development of adverse postinfarction myocardial remodeling.¹⁶³ It has been established that long-term treatment with BNP prevents postinfarction myocardial remodeling and disturbance of cardiac function supposedly through inhibition of TGF β1 signaling.^78,164 PKG is involved in BNP-induced inhibition of TGF β1 signaling.¹⁶⁴ Investigators found that BNP inhibits pro-fibrotic effect TGF β1 in human primary cardiac fibroblast.¹⁶⁵ TGF-β1 expression is markedly enhanced in Npr1-/- mouse hearts and suppressed in Npr1++/++ mouse hearts.³⁰ CNP induced downregulation of TGF-β1 in isolated perfused beating rat left atria.¹⁵⁷ In vitro, CD-NP (synthetic NP) reduced collagen production stimulated by TGF-β1 greater than BNP or CNP in isolated cardiac fibroblasts of patients with HF.³⁸

The presented data indicate that the anti-fibrotic effect of natriuretic peptides may be mediated through inhibition TGF-β1 expression.

Natriuretic Peptides and Transcription Factors

It is known that transcription factors are involved in the cardioprotective effect of pre- and postconditioning.^105,151 This is primarily signal transducer and activator of transcription (STAT) and nuclear factor kappa B (NFκB).¹⁵¹ There are no evince on involvement STAT in the infarct-reducing effect of natriuretic peptides. However, it was established that NFκB is involved in some cardiovascular effects of natriuretic peptides. Human umbilical vein endothelial cells (HUVEC) were pretreated with ANP before using TNF-α.¹⁶⁶ ANP reduced TNF-α-induced NF-κB activity and decreased translocation of p65 (one of NF-κB proteins) to nuclei.¹⁶⁶ It was established that TNF-α expression is enhanced by 8-fold in Npr1-/- mouse hearts compared with wild-type mouse hearts.³⁰ Myocardial fibrosis, total collagen, were increased in Npr1-/- mice compared wild-type animals. NF-κB activity in mouse ventricular tissues was enhanced by 4-fold and increased translocation of the p65 subunit from the cytoplasm to nuclei in Npr1-/- mice. CNP attenuated LPS-induced endothelial activation by inhibiting the NF-κB binding activity and eliminated LPS-induced intracellular ROS in HUVEC.⁹⁷ NF-κB binding activity was markedly decreased in Npr1++/++ mouse hearts compared with wild-type mice.³⁰

GATA transcription factors are a family of transcription factors that interact with GATA sequence in DNA and involved in the regulation of inflammation.¹⁶⁷ Pretreatment with GATA4 siRNA completely abolished the ability of ANP to inhibit endothelin-1 synthesis by isolated cardiac fibroblasts.¹⁴³

Thus, it has been shown that natriuretic peptides can inhibit NF-κB activity and suppress endothelin-1 synthesis through GATA activation.

Conclusion

The presented data indicate that natriuretic peptides have the infarct-limiting effect. Natriuretic peptides prevent reperfusion cardiac injury, prevent adverse post-infarction remodeling of the heart and increase survival of rats with experimental myocardial infarction. Atrial natriuretic peptide does not have the infarct-reducing effect in rats with alloxan-induced DM. Natriuretic peptides have the anti-apoptotic and anti-inflammatory effects. However, it is unclear to what extent their anti-inflammatory effect is involved in their infarction-sparing and antifibrotic effects. There is indirect evidence that natriuretic peptides inhibit pyroptosis and autophagy. Presented data indicate that natriuretic peptides inhibit ROS production in cardiomyocytes, aorta, heart, kidney and VSMC. Published data showed that natriuretic peptides can suppress aldosterone, angiotensin II, endothelin-1 synthesize and secretion and inhibit the effects aldosterone, angiotensin II on the post-receptor level through intracellular signaling events. Presented data indicate that natriuretic peptides activate guanylyl cyclase, activate PKG and PKA, and reduce the PDE-3 activity. However, it is unclear which of these changes provide increased cardiac tolerance to ischemia/reperfusion. NOS and soluble guanylyl cyclase are involved in the cardioprotective effect of natriuretic peptides. The cardioprotective effect of natriuretic peptides is mediated via activation of AMPK, PKC, PI3 K, MEK/ERK (ERK1/2), p70s6 k, Akt and inhibition of GSK-3β.The cardioprotective effect of natriuretic peptides is mediated via sarcK_ATP channel and mitoK_ATP channel opening. The cardioprotective effect of BNP is mediated via MPT pore closing. The anti-fibrotic effect of natriuretic peptides may be mediated through inhibition TGF-β1 expression. Natriuretic peptides can inhibit NF-κB activity and activate GATA. HO-1 and PPARγ may be involved in the infarct-reducing effect of natriuretic peptides.

Natriuretic peptides have the infarct-limiting effect in patients with STEMI. Natriuretic peptides prevent postinfarction remodeling of the heart. To finally resolve the question of the feasibility of using natriuretic peptides in AMI, a multicenter, randomized, blind, placebo-controlled study is needed to assess the effect of natriuretic peptides on the mortality of patients after AMI. We suggest that the use of cheap synthetic long-acting NPR agonists, which can be used in AMI, post-infarction remodeling of the heart, and cardiosurgical interventions using cardiopulmonary bypass, will open in a new era in the clinical use of natriuretic peptides.

Footnotes

Authors’ Note

This article was prepared with the support of a grant from the Russian Science Foundation16-15-10001. Section dedicated to kinases is framed within the framework of state assignments AAAA-A15-115120910024-0. Andrey V. Krylatov, Sergey Y. Tsibulnikova, Alexander V. Mukhomedzyanov, Alla A. Boshchenko, Victor E. Goldberg, Amteshwar S. Jaggi, Reinhold G. Erben contributed to acquisition, analysis, or interpretation and contributed to conception or design. Leonid N. Maslov contributed to acquisition, analysis, or interpretation; drafted the manuscript; and agreed to be accountable for all aspects of work ensuring integrity and accuracy. Attila Kiss contributed to acquisition, analysis, or interpretation; contributed to conception or design; drafted the manuscript; critically revised the manuscript; and agreed to be accountable for all aspects of work ensuring integrity and accuracy.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The article was prepared with the support of the Russian Science Foundation grant 16-15-10001.

ORCID iDs

Amteshwar S. Jaggi

Leonid N. Maslov

References

Zhou

Chen

Zhu

Gui

Abusaada

. Prior beta blockers use is independently associated with increased in patient mortality in patients presenting with acute myocardial infarction. Int J Cardiol. 2017;243:81–85.

Vaidya

Devarapally

Arora

. Infarct related artery only versus complete revascularization in ST-segment elevation myocardial infarction and multi vessel disease: a meta-analysis. Cardiovasc Diagn Ther. 2017;7(1):16–26.

Menees

Peterson

Wang

, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med. 2013;369(10):901–909.

McCartney

Berry

. Redefining successful primary PCI. Eur Heart J Cardiovasc Imaging. 2019;20(2):133–135.

Ndrepepa

. Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI. Coron Artery Dis. 2015;26(4):341–355.

Iliodromitis

Cohen

Dagres

Andreadou

Kremastinos

Downey

. What is wrong with cardiac conditioning? We may be shooting at moving targets. J Cardiovasc Pharmacol Ther. 2015;20(4):357–369.

Botker

Hausenloy

Andreadou

, et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol. 2018;113(5):39.

de Bold

Borenstein

Veress

Sonnenberg

. A Rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89–94.

Flynn

de Bold

. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun. 1983;117(3):859–865.

10.

Moghtadaei

Polina

Rose

. Electrophysiological effects of natriuretic peptides in the heart are mediated by multiple receptor subtypes. Prog Biophys Mol Biol. 2016;120(1-3):37–49.

11.

Kangawa

Matsuo

. Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Commun. 1984a;118(1):131–139.

12.

Kangawa

Fukuda

Minamino

Matsuo

. Purification and complete amino acid sequence of beta-rat atrial natriuretic polypeptide (β-rANP) of 5,000 daltons. Biochem Biophys Res Commun. 1984b;119(3):933–940.

13.

Sudoh

Kangawa

Minamino

Matsuo

. A New natriuretic peptide in porcine brain. Nature. 1988;332(6159):78–81.

14.

Sudoh

Kangawa

Minamino

Matsuo

. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990;168(2):863–870.

15.

Nishikimi

Maeda

Matsuoko

. The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006;69(2):318–328.

16.

Nakagawa

Nishikimi

Kuwahara

Atrial and brain natriuretic peptides: hormones secreted from the heart. Peptides. 2019;111:18–25.

17.

Jarai

Kaun

Weiss

, et al. Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1α, tumour necrosis factor-α and transforming growth factor-β. J Cell Mol Med. 2009;13(11-12):4415–4421.

18.

Hobbs

Foster

Prescott

Scotland

Ahluwalia

. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation. 2004;110(10):1231–1235.

19.

Forte

Madonna

Schiavon

, et al. Cardiovascular pleiotropic effects of natriuretic peptides. Int J Mol Sci. 2019;20(16):E3874.

20.

Nakao

Kuwahara

Nishikimi

, et al. Endothelium-derived C-type natriuretic peptide contributes to blood pressure regulation by maintaining endothelial integrity. Hypertension. 2017;69(2):286–296.

21.

Hunt

Richards

Espiner

Nicholls

Yandle

. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab. 1994;78(6):1428–1435.

22.

Benomar

Espiard

Loyer

Jannin

Vantyghem

. Atrial natriuretic hormones and metabolic syndrome: recent advances. Presse Med. 2018;47(2):116–124.

23.

Iwamoto

Yamaguchi

Sekiguchi

, et al. Pharmacokinetic and pharmacodynamic profiles of glyco-modified atrial natriuretic peptide derivatives synthesized using chemo-enzymatic synthesis approaches. Bioconjug Chem. 2018;29(8):2829–2837.

24.

Pandey

. Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function. Physiol Genomics. 2018;50(11):913–928.

25.

Sarkar

Brochu

Anand-Srivastava

. Natriuretic peptide receptor-C attenuates hypertension in spontaneously hypertensive rats: role of nitroxidative stress and Gi proteins. Hypertension. 2014;63(4):846–855.

26.

Moyes

Hobbs

. C-type natriuretic peptide: a multifaceted paracrine regulator in the heart and vasculature. Int J Mol Sci. 2019;20(9):E2281.

27.

Asanuma

Sanada

Asakura

, et al. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO. Hypertens Res. 2014;37(8):716–723.

28.

Burgess

Moore

Carter

, et al. C-type natriuretic peptide receptor expression in pancreatic alpha cells. Histochem Cell Biol. 2009;132(1):95–103.

29.

Anand-Srivastava

. Natriuretic peptide receptor-C signaling and regulation. Peptides. 2005;26(6):1044–1049.

30.

Vellaichamy

Das

Subramanian

Maeda

Pandey

. Genetically altered mutant mouse models of guanylyl cyclase/natriuretic peptide receptor-A exhibit the cardiac expression of proinflammatory mediators in a gene-dose-dependent manner. Endocrinology. 2014;155(3):1045–1056.

31.

Moyes

Khambata

Villar

, et al. Endothelial C-type natriuretic peptide maintains vascular homeostasis. J Clin Invest. 2014;124(9):4039–4051.

32.

Spiranec

Chen

Werner

, et al. Endothelial C-type natriuretic peptide acts on pericytes to regulate microcirculatory flow and blood pressure. Circulation. 2018;138(5):494–508.

33.

Moyes

Chu

Aubdool

, et al. C-type natriuretic peptide co-ordinates cardiac structure and function. Eur Heart J. 2020;41(9):1006–1020.

34.

Yan

Morser

. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA. 2000;97(15):8525–8529.

35.

Celik

Karbalaei-Sadegh

Rådegran

Smith

Gidlöf

. Functional screening identifies microRNA regulators of corin activity and atrial natriuretic peptide biogenesis. Mol Cell Biol. 2019;39(23):e00271–19.

36.

Chen

Cao

Dong

, et al. PCSK6-mediated corin activation is essential for normal blood pressure. Nat Med. 2015;21(9):1048–1053.

37.

Sawada

Inoue

Kanda

, et al. Co-elevation of brain natriuretic peptide and proprotein-processing endoprotease furin after myocardial infarction in rats. FEBS Lett. 1997;400(2):177–182.

38.

Ichiki

Boerrigter

Huntley

, et al. Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol. 2013;304(2):R102–109.

39.

Kato

. Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage. Peptides. 2020;132:170352.

40.

Ronkainen

Vuolteenaho

Tavi

. Calcium-calmodulin kinase II is the common factor in calcium-dependent cardiac expression and secretion of A- and B-type natriuretic peptides. Endocrinology. 2007;148(6):2815–2820.

41.

Rankin

Wilson

Ledsome

. Effects of autonomic stimulation on plasma immunoreactive atrial natriuretic peptide in the anesthetized rabbit. Can J Physiol Pharmacol. 1987;65(4):532–537.

42.

Valette

Lemoine

Allouche

Gérard

Hanouz

. Effect of lipopolysaccharide, cytokines, and catecholamines on brain natriuretic peptide release from human myocardium. Acta Anaesthesiol Scand. 2012;56(7):860–865.

43.

Yuan

Rhee

Park

Kim

. Different response of ANP secretion to adrenoceptor stimulation in renal hypertensive rat atria. Peptides. 2008;29(7):1207–1215.

44.

Casals

Ros

Sionis

Davidson

Morales-Ruiz

Jiménez

. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol. 2009;297(2):H550–H555.

45.

Xia

Huang

Chen

. Acute myocardial ischemia directly modulates the expression of brain natriuretic peptide at the transcriptional and translational levels via inflammatory cytokines. Eur J Pharmacol. 2011;670(1):7–12.

46.

Cai

Zhou

. The relationship between the changes in plasma atrial natriuretic peptide and renin angiotensin contents and hemodynamics in pulmonary hypertensive rats. Chin Med Sci J. 1992;7(1):36–39.

47.

Yuan

Kim

, et al. Upregulation of ANP and NPR-C mRNA in the kidney and heart of eNOS knockout mice. Peptides. 2010;31(7):1319–1325.

48.

Amador-Martinez

Pérez-Villalva

Uribe

Cortés-González

Bobadilla

Barrera-Chimal

. Reduced endothelial nitric oxide synthase activation contributes to cardiovascular injury during chronic kidney disease progression. Am J Physiol Renal Physiol. 2019;317(2):F275–285.

49.

D’Souza

Yellon

Martin

, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via K_ATP channel opening. Am J Physiol Heart Circ Physiol. 2003;284(5):1592–1600.

50.

Cohen

Downey

. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. 2015;172 (8):1913–1932.

51.

Okawa

Horimoto

Mieno

Nomura

Yoshida

Shinjiro

. Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts. Mol Cell Biochem. 2003;248(1-2):171–177.

52.

Burley

Baxter

. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol. 2007;102(6):529–541.

53.

Takagi

Kiuchi

Endo

, et al. α-Human atrial natriuretic peptide, carperitide, reduces infarct size but not arrhythmias after coronary occlusion/reperfusion in dogs. J Cardiovasc Pharmacol. 2000;36(1):22–30.

54.

Zhang

Hasaniya

Premaratne

McNamara

. Atrial natriuretic peptide protects against ischemia-reperfusion injury in rabbit hearts in vivo. Vasc Endovascular Surg. 2008;42(3):263–267.

55.

Pan

Zhu

, et al. Therapeutic effects of continuous infusion of brain natriuretic peptides on postmyocardial infarction ventricular remodeling in rats. Arch Cardiovasc Dis. 2011;104(1):17–28.

56.

Franco

Chen

Feng

, et al. Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice. Clin Exp Pharmacol Physiol. 2006;33(9):773–779.

57.

Ellmers

Knowles

Kim

Smithies

Maeda

Cameron

. Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol. 2002;283(2):H707–714.

58.

Ishii

Kaikita

Sato

, et al. Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage. Cardioprotective effects of LCZ696 (sacubitril/valsartan) after experimental acute myocardial infarction. JACC Basic Transl Sci. 2017;2(6):655–668.

59.

Rahmutula

Zhang

Wilson

Olgin

. Absence of natriuretic peptide clearance receptor attenuates TGF-β1-induced selective atrial fibrosis and atrial fibrillation. Cardiovasc Res. 2019;115(2):357–372.

60.

Charan

Goyal

Gupta

Yadav

. Role of atrial natriuretic peptide in ischemic preconditioning-induced cardioprotection in the diabetic rat heart. J Surg Res. 2016;201(2):272–278.

61.

Pieske

Kraigher-Krainer

. Diabetes mellitus, natriuretic peptide axis dysregulation, and diabetic cardiomyopathy. Eur J Heart Fail. 2010;12(9):898–900.

62.

Malek

Sharma

Gaikwad

. Histone acetylation regulates natriuretic peptides and neprilysin gene expressions in diabetic cardiomyopathy and nephropathy. Curr Mol Pharmacol. 2019;12(1):61–71.

63.

Ruocco

Evangelista

Franci

, et al. Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome. J Cardiovasc Med (Hagerstown). 2019;20(2):81–90.

64.

Andreadou

Bell

Bøtker

Zuurbier

. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochim Biophys Acta Mol Basis Dis. 2020b;1866(7):165770.

65.

Packer

Lam

CSP

Lund

Maurer

Borlaug

. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail. 2020;22(4):618–628.

66.

Yurista

Silljé

HHW

Oberdorf-Maass

, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21(7):862–873.

67.

Damman

Beusekamp

Boorsma

, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713–722.

68.

de Boer

Núñez

Kozlovski

Wang

Proot

Keefe

. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. Br J Clin Pharmacol. 2020;86(7):1346–1356.

69.

Tripolt

Kolesnik

Pferschy

, et al. EMMY study group. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial. Am Heart J. 2020;221:39–47.

70.

Yang

Philipp

Downey

Cohen

. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol. 2006;101(4):311–318.

71.

Huang

Zhang

Jiang

. Anti-inflammatory effect of B-type natriuretic peptide postconditioning during myocardial ischemia-reperfusion: involvement of PI3K/Akt signaling pathway. Inflammation. 2014;37(5):1669–1674.

72.

Breivik

Jensen

Guvåg

, et al. B-type natriuretic peptide expression and cardioprotection is regulated by Akt dependent signaling at early reperfusion. Peptides. 2015;66:43–50.

73.

Sun

Zhang

Yan

Zheng

. B-type natriuretic peptide-induced cardioprotection against reperfusion is associated with attenuation of mitochondrial permeability transition. Biol Pharm Bull. 2009;32(9):1545–1551.

74.

Tourki

Dumesnil

Belaidi

, et al. Lebetin 2, a snake venom-derived B-type natriuretic peptide, provides immediate and prolonged protection against myocardial ischemia-reperfusion injury via modulation of post-ischemic inflammatory response. Toxins (Basel). 2019;11(9):E524.

75.

Fujii

Ishino

Tomii

, et al. Atrionatriuretic peptide improves left ventricular function after myocardial global ischemia-reperfusion in hypoxic hearts. Artif Organs. 2012;36(4):379–386.

76.

Soeki

Kishimoto

Okumura

, et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2005;45(4):608–616.

77.

Wang

de Waard

Sterner-Kock

, et al. Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail. 2007;9(6-7):548–557.

78.

Chen

Huang

, et al. Effect of long-term B-type natriuretic peptide treatment on left ventricular remodeling and function after myocardial infarction in rats. Eur J Pharmacol. 2009;602(1):132–137.

79.

Izumiya

Araki

Usuku

Rokutanda

Hanatani

Ogawa

. Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling. Int J Vasc Med. 2012;2012:246058.

80.

Romson

Hook

Kunkel

Abrams

Schork

Lucchesi

. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation. 1983;67(5):1016–1023.

81.

Ferrari

Lueneberg

da Silva

Fattah

Gottschall

CAM

Moreira

. Correlation between leukocyte count and infarct size in ST segment elevation myocardial infarction. Arch Med Sci Atheroscler Dis. 2016;1(1):e44–e48.

82.

Patel

Valencik

Pritchett

Burnett

McDonald

Redfield

. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol. 2005;289(2):H777–784.

83.

Martin

Sangaralingham

Huntley

, et al. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One. 2012;7(12):e52422.

84.

Ichiki

Schirger

Huntley

, et al. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications. J Mol Cell Cardiol. 2014;75:199–205.

85.

Jiang

Lin

Cui

Wen

. Pretreatment with B-type natriuretic peptide protects the heart from ischemia-reperfusion injury by inhibiting myocardial apoptosis. Tohoku J Exp Med. 2009;219(2):107–114.

86.

Deng

Tan

Zeng

Dong

. Effects of BNP preconditioning on myocardial cell apoptosis and expressions of bcl 2 and Bax during myocardial ischemia-reperfusion injury in rats. Zhonghua Yi Xue Za Zhi. 2010;90(48):3431–3434.

87.

Sun

Deng

Yan

Zheng

. B-type natriuretic peptide protects cardiomyocytes at reperfusion via mitochondrial calcium uniporter. Biomed Pharmacother. 2010;64(3):170–176.

88.

Chang

Zhang

, et al. B-type natriuretic peptide attenuates endoplasmic reticulum stress in H9c2 cardiomyocytes underwent hypoxia/reoxygenation injury under high glucose/high fat conditions. Peptides. 2019;111:103–111.

89.

Wang

Zeng

Zheng

. B-type natriuretic peptide enhances mild hypoxia-induced apoptotic cell death in cardiomyocytes. Biol Pharm Bull. 2007;30(6):1084–1090.

90.

Jorgensen

Miao

. Pyroptotic cell death defends against intracellular pathogens. Immunol Rev. 2015;265(1):130–142.

91.

Mezzasoma

Antognelli

Talesa

. Atrial natriuretic peptide down-regulates LPS/ATP-mediated IL-1β release by inhibiting NF-kB, NLRP3 inflammasome and caspase-1activation in THP-1 cells. Immunol Res. 2016;64(1):303–312.

92.

Mezzasoma

Antognelli

Talesa

. A novel role for brain natriuretic peptide: inhibition of IL-1β secretion via downregulation of NF-kB/Erk 1/2 and NALP3/ASC/caspase-1 activation in human THP-1 monocyte. Mediators Inflamm. 2017;2017:5858315.

93.

Lou

Palikaras

Lautrup

Scheibye-Knudsen

Tavernarakis

Fang

. Mitophagy and neuroprotection. Trends Mol Med. 2020;26(1):8–20.

94.

Liu

Ceddia

Collins

. Cardiac natriuretic peptides promote adipose ‘browning’ through mTOR complex-1. Mol Metab. 2018;9:192–198.

95.

Andreadou

Schulz

Papapetropoulos

, et al. The role of mitochondrial reactive oxygen species, NO and H2 S in ischaemia/reperfusion injury and cardioprotection. J Cell Mol Med. 2020a;24(12):6510–6522.

96.

Krylatov

Maslov

Voronkov

, et al. Reactive oxygen species as intracellular signaling molecules in the cardiovascular system. Curr Cardiol Rev. 2018;14(4):290–300.

97.

Chen

Zhao

Yin

, et al. C-type natriuretic peptide attenuates LPS-induced endothelial activation: involvement of p38, Akt, and NF-κB pathways. Amino Acids. 2014;46(12):2653–2663.

98.

Hsu

Liou

Yang

, et al. B-type natriuretic peptide inhibits angiotensin II-induced proliferation and migration of pulmonary arterial smooth muscle cells. Pediatr Pulmonol. 2014;49(8):734–744.

99.

Murakami

Kobayashi

Susa

, et al. Recombinant atrial natriuretic peptide prevents aberrant Ca²⁺ leakage through the ryanodine receptor by suppressing mitochondrial reactive oxygen species production induced by isoproterenol in failing cardiomyocytes. PLoS One. 2016;11(9):e0163250.

100.

Jain

Anand-Srivastava

. Natriuretic peptide receptor-C-mediated attenuation of vascular smooth muscle cell hypertrophy involves Gqα/PLCβ1 proteins and ROS-associated signaling. Pharmacol Res Perspect. 2018;6(1):e00375.

101.

Rahali

Anand-Srivastava

. Contribution of oxidative stress and growth factor receptor transactivation in natriuretic peptide receptor C-mediated attenuation of hyperproliferation of vascular smooth muscle cells from SHR. PLoS One. 2018;13(1):e0191743.

102.

Madiraju

Hossain

Anand-Srivastava

. Natriuretic peptide receptor-C activation attenuates angiotensin II-induced enhanced oxidative stress and hyperproliferation of aortic vascular smooth muscle cells. Mol Cell Biochem. 2018;448(1-2):77–89.

103.

Gao

Yuan

Shah

Kim

Park

Kim

. Suppression of high pacing-induced ANP secretion by antioxidants in isolated rat atria. Peptides. 2011;32(12):2467–2473.

104.

Pernomian

Prado

Silva

, et al. C-type natriuretic peptide induces anti-contractile effect dependent on nitric oxide, oxidative stress, and NPR-B activation in sepsis. Front Physiol. 2016;7:226.

105.

Heusch

. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015;116(4):674–699.

106.

Oldenburg

Qin

Krieg

, et al. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol. 2004;286(1):H468–H476.

107.

Kitakaze

Asakura

Kim

, et al. J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370(9597):1483–1493.

108.

Dai

, et al. Effects of pretreatment with recombinant human B-type natriuretic peptide on infarct size in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi. 2015;43(11):954–959.

109.

Sezai

Hata

Niino

, et al. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol. 2010;55(17):1844–1851.

110.

Hayashi

Tsutamoto

Wada

, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37(7):1820–1826.

111.

Kuga

Ogawa

Oida

, et al. Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. Circ J. 2003;67(5):443–448.

112.

Isogai

Matsui

Tanaka

Fushimi

Yasunaga

. Atrial natriuretic peptide therapy and in-hospital mortality in acute myocardial infarction patients undergoing percutaneous coronary intervention. Int J Cardiol. 2016;222:163–170.

113.

Mukaida

Hayashida

Matsushita

, et al. Free triiodothyronine (fT3) and B-type natriuretic peptide (BNP) predict in-hospital mortality after valve surgery. Gen Thorac Cardiovasc Surg. 2020;68(6):585–595 .

114.

Polineni

Parker

Alam

, et al. Predictive ability of novel cardiac biomarkers ST2, galectin-3, and NT-ProBNP before cardiac surgery. J Am Heart Assoc. 2018;7(14):e008371.

115.

Kontos

Lanfear

Gosch

Daugherty

Heidenriech

Spertus

. Prognostic value of serial N-terminal pro-brain natriuretic peptide testing in patients with acute myocardial infarction. Am J Cardiol. 2017;120(2):181–185.

116.

Huang

Tseng

Chu

, et al. N-terminal pro b-type natriuretic peptide (NT-pro-BNP) -based score can predict in-hospital mortality in patients with heart failure. Sci Rep. 2016;6:29590.

117.

Leppäluoto

Arjamaa

Vuolteenaho

Ruskoaho

. Passive heat exposure leads to delayed increase in plasma levels of atrial natriuretic peptide in humans. Appl Physiol (1985) . 1991;71(2):716–720.

118.

Prabhu

Frangogiannis

. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119(1):91–112.

119.

Yiang

Liao

, et al. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 2018;46(4):1650–1667.

120.

Mtairag el

Houard

Rais

, et al. Pharmacological potentiation of natriuretic peptide limits polymorphonuclear neutrophil-vascular cell interactions. Arterioscler Thromb Vasc Biol. 2002;22(11):1824–1831.

121.

Fujita

Shimojo

Terasaki

, et al. Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade. Heart Vessels. 2013;28(5):646–657.

122.

Weber

Blumenthal

Hartung

Vollmar

Kiemer

. ANP inhibits TNF-α-induced endothelial MCP-1 expression—involvement of p38 MAPK and MKP-1. J Leukoc Biol. 2003;74(5):932–941.

123.

Ladetzki-Baehs

Keller

Kiemer

, et al. Atrial natriuretic peptide, a regulator of nuclear factor-κB activation in vivo. Endocrinology. 2007;148(1):332–336.

124.

Chiurchiu

Izzi

D’Aquilio

Carotenuto

Di Nardo

Baldini

. Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept. 2008;148(1-3):26–32.

125.

Vellaichamy

Khurana

Fink

Pandey

. Involvement of the NF-κB/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A. J Biol Chem. 2005;280(19):19230–19242.

126.

Koga

Hagiwara

Shingu

Matsumoto

Yokoi

Noguchi

. Human atrial natriuretic peptide ameliorates LPS-induced acute lung injury in rats. Lung. 2010;188(3):241–246.

127.

Zhu

Zhang

Liu

, et al. Atrial natriuretic peptide attenuates inflammatory responses on oleic acid-induced acute lung injury model in rats. Chin Med J (Engl). 2013;126(4):747–750.

128.

Song

Cui

Ding

Jin

Gao

. Protective effects of recombinant human brain natriuretic peptide against LPS-induced acute lung injury in dogs. Int Immunopharmacol. 2013;17(3):508–512.

129.

Andersson

Yang

Harris

. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets. 2018;22(3):263–277.

130.

Chen

Song

Yin

, et al. C-type natriuretic peptide prevents kidney injury and attenuates oxidative and inflammatory responses in hemorrhagic shock. Amino Acids. 2017;49(2):347–354.

131.

Liu

, et al. Inhibitory effects of C-type natriuretic peptide on the differentiation of cardiac fibroblasts, and secretion of monocyte chemoattractant protein-1 and plasminogen activator inhibitor-1. Mol Med Rep. 2015;11(1):159–165.

132.

Caniffi

Prentki Santos

Cerniello

, et al. Cardiac morphological and functional changes induced by C-type natriuretic peptide are different in normotensive and spontaneously hypertensive rats. J Hypertens. 2020.

133.

Porter

Turner

. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009;123(2):255–278.

134.

Jugdutt

Menon

. AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction. Mol Cell Biochem. 2004;260(1-2):111–118.

135.

Messadi-Laribi

Griol-Charhbili

Pizard

, et al. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther. 2007;323(1):210–216.

136.

Ozdemir

Parlakpinar

Polat

Colak

Ermis

Acet

. Selective endothelin a (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology. 2006;219(1-3):142–149.

137.

Spiessberger

Bernhard

Herrmann

, et al. cGMP-dependent protein kinase II and aldosterone secretion. FEBS J. 2009;276(4):1007–1013.

138.

Takahashi

Saito

Kuwahara

, et al. Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. Hypertens Res. 2003;26(10):847–853.

139.

Parthasarathy

Gopi

Umadevi

, et al. Suppression of atrial natriuretic peptide/natriuretic peptide receptor-A-mediated signaling upregulates angiotensin-II-induced collagen synthesis in adult cardiac fibroblasts. Mol Cell Biochem. 2013;378(1-2):217–228.

140.

Nakagawa

Oberwinkler

Nikolaev

, et al. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation. Circ Heart Fail. 2014;7(5):814–821.

141.

Miura

Nakayama

Tomita

Matsuo

Suematsu

Saku

. Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide. Clin Exp Hypertens. 2015;37(5):353–357.

142.

Uemasu

Matsumoto

Kitano

Kawasaki

. Suppression of plasma endothelin-1 level by α-human atrial natriuretic peptide and angiotensin converting enzyme inhibition in normal men. Life Sci. 1993;53(11):969–974.

143.

Glenn

Rahmutula

Nishimoto

Liang

Gardner

. Atrial natriuretic peptide suppresses endothelin gene expression and proliferation in cardiac fibroblasts through a GATA4-dependent mechanism. Cardiovasc Res. 2009;84(2):209–217.

144.

Cohen

Downey

. Cardioprotection: spotlight on PKG. Br J Pharmacol. 2007;152(6):833–834.

145.

Qvigstad

Moltzau

Aronsen

, et al. Natriuretic peptides increase β1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res. 2010;85(4):763–772.

146.

Chan

Seyedi

Takano

Levi

. An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition. Circulation. 2012a;125(2):298–307.

147.

Chan

Robador

Levi

. Natriuretic peptide-induced catecholamine release from cardiac sympathetic neurons: inhibition by histamine H3 and H4 receptor activation. J Pharmacol Exp Ther. 2012b;343(3):568–577.

148.

Meier

Andressen

Aronsen

, et al. PDE3 inhibition by C-type natriuretic peptide-induced cGMP enhances cAMP-mediated signaling in both non-failing and failing hearts. Eur J Pharmacol. 2017;812:174–183.

149.

Lishmanov

Maslov

Mukhomedzyanov

. Role of β-adrenoceptors and L-type Ca²⁺-channels in the mechanism of reperfusion-induced heart injury. Bull Exp Biol Med. 2016;161(1):20–23.

150.

Khaliulin

Bond

James

, et al. Functional and cardioprotective effects of simultaneous and individual activation of protein kinase A and Epac. Br J Pharmacol. 2017;174(6):438–453.

151.

Tsibulnikov

Maslov

Gorbunov

, et al. A review of humoral factors in remote preconditioning of the heart. J Cardiovasc Pharmacol Ther. 2019;24(5):403–421.

152.

Carini

De Cesaris

Splendore

, et al. Mechanisms of hepatocyte protection against hypoxic injury by atrial natriuretic peptide. Hepatology. 2003;37(2):277–285.

153.

Kook

Itoh

Choi

, et al. Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro. Am J Physiol Heart Circ Physiol. 2003;284(4):H1388–1397.

154.

Hashim

Anand-Srivastava

. Small cytoplasmic domain peptides of natriuretic peptide Receptor-C attenuate cell proliferation through Giα protein/MAP kinase/PI3-kinase/AKT pathways. Am J Physiol Heart Circ Physiol. 2006;291(6):H3144–3153.

155.

Hong

Zhang

, et al. Atrial natriuretic peptide prevents the mitochondrial permeability transition pore opening by inactivating glycogen synthase kinase3β via PKG and PI3 K in cardiac H9c2 cells. Eur J Pharmacol. 2012;695(1-3):13–19.

156.

Zhang

Pan

Aisha

Abudoukelimu

Tang

Ling

. Recombinant human brain natriuretic peptide regulates PI3K/AKT/mTOR pathway through lncRNA EGOT to attenuate hypoxia-induced injury in H9c2 cardiomyocytes. Biochem Biophys Res Commun. 2018;503(3):1186–1193.

157.

Ding

Jia

Zhang

, et al. C type natriuretic peptide prevents angiotensin II induced atrial connexin 40 and 43 dysregulation by activating AMP activated kinase signaling. Mol Med Rep. 2019;20(6):5091–5099.

158.

Caniffi

Elesgaray

Gironacci

Arranz

Costa

. C-type natriuretic peptide effects on cardiovascular nitric oxide system in spontaneously hypertensive rats. Peptides. 2010;31(7):1309–1318.

159.

Zhong

Chen

Zhou

Wang

. The role of peroxisome proliferator-activated receptor γ in mediating cardioprotection against ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther. 2018;23(1):46–56.

160.

Suzuki

Saiki

Horii

, et al. Atrial natriuretic peptide induces peroxisome proliferator activated receptor γ during cardiac ischemia-reperfusion in swine heart. Gen Thorac Cardiovasc Surg. 2017;65(2):85–95.

161.

Burley

Cox

Zhang

Wann

Baxter

. Natriuretic peptides modulate ATP-sensitive K(+) channels in rat ventricular cardiomyocytes. Basic Res Cardiol. 2014;109(2):402.

162.

Naryzhnaya

Maslov

Oeltgen

. Pharmacology of mitochondrial permeability transition pore inhibitors. Drug Dev Res. 2019;80(8):1013–1030.

163.

Ayca

Sahin

Kucuk

, et al. Increased transforming growth factor-β levels associated with cardiac adverse events in hypertrophic cardiomyopathy. Clin Cardiol. 2015; 38(6): 371–377.

164.

Chen

, et al. B-type natriuretic peptide attenuates cardiac hypertrophy via the transforming growth factor-ß1/smad7 pathway in vivo and in vitro. Clin Exp Pharmacol Physiol. 2010;37(3):283–289.

165.

Watson

Phelan

, et al. Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-β mediated fibrosis. Fibrogenesis Tissue Repair. 2012;5(1):9.

166.

Kiemer

Weber

Vollmar

. Induction of IκB: atrial natriuretic peptide as a regulator of the NF-κB pathway. Biochem Biophys Res Commun. 2002;295(5):1068–1076.

167.

Tanriver

Diefenbach

. Transcription factors controlling development and function of innate lymphoid cells. Int Immunol. 2014;26(3):119–128.

The Role of Natriuretic Peptides in the Regulation of Cardiac Tolerance to Ischemia/Reperfusion and Postinfarction Heart Remodeling

Abstract

Keywords

Introduction

Data From Experimental Studies

Infarct-Reducing Effect of Natriuretic Peptides

Natriuretic Peptides and Postinfarction Myocardial Remodeling

Natriuretic Peptides, Apoptosis, Pyroptosis and Autophagy

Natriuretic Peptides and ROS

Data From Clinical Studies

Natriuretic Peptides as Predictors of Mortality

Potential Mechanisms Underlying the Infarct-Reducing and Anti-Fibrotic Effects of Natriuretic Peptides

Anti-Inflammatory Effect of Natriuretic Peptides

Natriuretic Peptides, Angiotensin II, Aldosterone, Endothelin-1

Natriuretic Peptides, cAMP, cGMP, PKG

Natriuretic Peptides and Protein Kinases

Natriuretic Peptides and NO-Synthase

Natriuretic Peptides, HO-1 and PPARγ

Natriuretic Peptides, KATP Channels and MPT Pore

Natriuretic Peptides and TGF-β1

Natriuretic Peptides and Transcription Factors

Conclusion

Footnotes

Authors’ Note

Declaration of Conflicting Interests

Funding

ORCID iDs

References

Natriuretic Peptides, K_ATP Channels and MPT Pore